FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214809863> ?p ?o ?g. }

• W3214809863 endingPage "1723" @default.
• W3214809863 startingPage "1714" @default.
• W3214809863 abstract "BACKGROUND: Three novel acute treatments for migraine—lasmiditan, ubrogepant, and rimegepant—were approved by the FDA in 2019 and 2020 for adults with migraine with and without aura. American Headache Society guidance recommends that these novel acute treatments be considered for patients who are contraindicated to or fail to respond or tolerate oral triptans, the current standard of acute care. OBJECTIVE: To estimate, from a US commercial plan perspective, the budget impact of adding lasmiditan as an option to a formulary that already includes ubrogepant and rimegepant. METHODS: Epidemiologic data were drawn from US Census data, the American Migraine Prevalence and Preventive study, and the first wave of the OVERCOME US survey, a web-based survey that included 21,000 patients with migraine. A model with a 3-year time horizon was built assuming that demand for the novel acute treatments would not vary based on whether lasmiditan is included in the formulary. The model examined a variety of populations, in particular beneficiaries with previous use of 1 or more oral triptans or contraindicated to triptans and beneficiaries with previous use of 2 or more oral triptans or contraindicated to triptans. Primary outcomes were the incremental differences in total cost and average cost per member per month (PMPM) between scenarios with and without lasmiditan. One-way sensitivity analyses with model parameters that were varied by plus or minus 15% were conducted to assess the effect of key parameters on the incremental total cost over 3 years. RESULTS: The addition of lasmiditan to a formulary that already includes ubrogepant and rimegepant resulted in a total savings of −$927,657 (−1.5% compared with the scenario without lasmiditan) over a 3-year time horizon in the population with previous history of using 1 or more oral triptans or contraindicated to a triptan. In the population with previous history of using 2 or more oral triptans or contraindicated, the addition of lasmiditan resulted in a total budget impact of −$466,518 (−1.3%) over a 3-year time horizon. Most of the cost savings was attributable to reductions in drug acquisition cost. Savings in total costs resulted in average incremental cost per PMPM of −0.03 and −$0.01, respectively. CONCLUSIONS: The addition of lasmiditan to the formulary as a novel acute treatment option for migraine alongside ubrogepant and rimegepant resulted in lower budget impact on a 3-year time horizon from a US commercial payer’s perspective. This result is important to US commercial payers as they seek to incorporate the emerging novel acute treatments for migraine into their benefit designs. DISCLOSURES: This work was funded by Eli Lilly and Company. Milev and Sun are employed by Evidera, which received funding from Eli Lilly and Company for work on this project. Pohl, Mason, Njuguna, and Loo are employees and stockholders of Eli Lilly and Company." @default.
• W3214809863 created "2021-12-06" @default.
• W3214809863 creator A5021204117 @default.
• W3214809863 creator A5026853808 @default.
• W3214809863 creator A5040259269 @default.
• W3214809863 creator A5076978088 @default.
• W3214809863 creator A5077663203 @default.
• W3214809863 creator A5079819010 @default.
• W3214809863 date "2021-12-01" @default.
• W3214809863 modified "2023-09-23" @default.
• W3214809863 title "Budget impact of lasmiditan for the acute treatment of migraine in the United States" @default.
• W3214809863 cites W1980229633 @default.
• W3214809863 cites W1981638246 @default.
• W3214809863 cites W2020568108 @default.
• W3214809863 cites W2047041272 @default.
• W3214809863 cites W2047455969 @default.
• W3214809863 cites W2057556593 @default.
• W3214809863 cites W2076003266 @default.
• W3214809863 cites W2084304739 @default.
• W3214809863 cites W2091270761 @default.
• W3214809863 cites W2116452736 @default.
• W3214809863 cites W2142670324 @default.
• W3214809863 cites W2153833732 @default.
• W3214809863 cites W2158846562 @default.
• W3214809863 cites W2166530830 @default.
• W3214809863 cites W2168800777 @default.
• W3214809863 cites W2260435540 @default.
• W3214809863 cites W2534944171 @default.
• W3214809863 cites W2559000357 @default.
• W3214809863 cites W2791199217 @default.
• W3214809863 cites W2801085490 @default.
• W3214809863 cites W2969260382 @default.
• W3214809863 cites W2990037077 @default.
• W3214809863 cites W2994337559 @default.
• W3214809863 cites W2999849670 @default.
• W3214809863 cites W3095455587 @default.
• W3214809863 cites W3116797659 @default.
• W3214809863 cites W4244823958 @default.
• W3214809863 doi "https://doi.org/10.18553/jmcp.2021.27.12.1714" @default.
• W3214809863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34818093" @default.
• W3214809863 hasPublicationYear "2021" @default.
• W3214809863 type Work @default.
• W3214809863 sameAs 3214809863 @default.
• W3214809863 citedByCount "0" @default.
• W3214809863 crossrefType "journal-article" @default.
• W3214809863 hasAuthorship W3214809863A5021204117 @default.
• W3214809863 hasAuthorship W3214809863A5026853808 @default.
• W3214809863 hasAuthorship W3214809863A5040259269 @default.
• W3214809863 hasAuthorship W3214809863A5076978088 @default.
• W3214809863 hasAuthorship W3214809863A5077663203 @default.
• W3214809863 hasAuthorship W3214809863A5079819010 @default.
• W3214809863 hasBestOaLocation W32148098631 @default.
• W3214809863 hasConcept C100406419 @default.
• W3214809863 hasConcept C104863432 @default.
• W3214809863 hasConcept C126322002 @default.
• W3214809863 hasConcept C142724271 @default.
• W3214809863 hasConcept C170493617 @default.
• W3214809863 hasConcept C177713679 @default.
• W3214809863 hasConcept C194828623 @default.
• W3214809863 hasConcept C204787440 @default.
• W3214809863 hasConcept C27081682 @default.
• W3214809863 hasConcept C2776738588 @default.
• W3214809863 hasConcept C2777030092 @default.
• W3214809863 hasConcept C2777119127 @default.
• W3214809863 hasConcept C2778541695 @default.
• W3214809863 hasConcept C2778871607 @default.
• W3214809863 hasConcept C2778938600 @default.
• W3214809863 hasConcept C3017807917 @default.
• W3214809863 hasConcept C42219234 @default.
• W3214809863 hasConcept C512399662 @default.
• W3214809863 hasConcept C71924100 @default.
• W3214809863 hasConceptScore W3214809863C100406419 @default.
• W3214809863 hasConceptScore W3214809863C104863432 @default.
• W3214809863 hasConceptScore W3214809863C126322002 @default.
• W3214809863 hasConceptScore W3214809863C142724271 @default.
• W3214809863 hasConceptScore W3214809863C170493617 @default.
• W3214809863 hasConceptScore W3214809863C177713679 @default.
• W3214809863 hasConceptScore W3214809863C194828623 @default.
• W3214809863 hasConceptScore W3214809863C204787440 @default.
• W3214809863 hasConceptScore W3214809863C27081682 @default.
• W3214809863 hasConceptScore W3214809863C2776738588 @default.
• W3214809863 hasConceptScore W3214809863C2777030092 @default.
• W3214809863 hasConceptScore W3214809863C2777119127 @default.
• W3214809863 hasConceptScore W3214809863C2778541695 @default.
• W3214809863 hasConceptScore W3214809863C2778871607 @default.
• W3214809863 hasConceptScore W3214809863C2778938600 @default.
• W3214809863 hasConceptScore W3214809863C3017807917 @default.
• W3214809863 hasConceptScore W3214809863C42219234 @default.
• W3214809863 hasConceptScore W3214809863C512399662 @default.
• W3214809863 hasConceptScore W3214809863C71924100 @default.
• W3214809863 hasIssue "12" @default.
• W3214809863 hasLocation W32148098631 @default.
• W3214809863 hasLocation W32148098632 @default.
• W3214809863 hasOpenAccess W3214809863 @default.
• W3214809863 hasPrimaryLocation W32148098631 @default.
• W3214809863 hasRelatedWork W1984045891 @default.
• W3214809863 hasRelatedWork W2040945213 @default.
• W3214809863 hasRelatedWork W2069962186 @default.

• next